Pro Medicus Limited (ASX: PME) shares have gone gangbusters over the past 5 years as the market wakes up to its growth story that straddles the lucrative healthcare and software sectors.
The stock joined the S&P/ASX 2oo (ASX: XJO) index of leading companies on June 24 2019 in a move that saw it receive more buying support from index-tracking funds and institutional investors.
The index inclusion also brought more professional research analyst coverage, with Goldman Sachs releasing an updated research note on November 24, 2o19.
Goldman’s has actually reduced its earnings per share forecasts by around 10% on average through fiscal 2020 to 2022 and consequently lowered its 12-month share price target by a $1 to $26.50.
The analysts are forecasting Pro Medicus to earn 23 cents per share in fiscal 2020 to place the stock at $26.49 per share on 115x estimated forward earnings. The earnings multiple reduces to 85x for fiscal 2021 based on estimates for 31 cents in earnings per share.
Pro Medicus is widely regarded as a ‘high-quality’ business, but it’s not going to smoke out the value investors on these kinds of frothy multiples.
Elsewhere, Goldman’s has a ‘sell’ rating on Ramsay Health Care Ltd (ASX: RHC) and Fisher & Paykel Healthcare (ASX: FPH).
The post Top broker downgrades Pro Medicus’s profit forecasts appeared first on Motley Fool Australia.
Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares for 2019
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2019
- 5 Stocks for Potentially Building Wealth After 50
Tom Richardson has no position in any stock mentioned.
You can find Tom on Twitter @tommyr345
The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia has recommended Pro Medicus Ltd. and Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019